Ketamine molecule:

Image from PubChem

Ketamine Clinical Trials

Intermittent infusion of lidocaine, magnesium sulphate and ketamine in the treatment of neuropathic pain, Chronic Regional Pain Syndrome and fibromyalgia. A pilot study.

To see complete record on, please visit this link

Id: ACTRN12619000494134p

Organisation Name: Daniel Ellyard

Overal Status: Not yet recruiting

Start Date: 15/04/2019

Brief Summary: Intermittent infusions utilising lidocaine, magnesium or ketamine are routinely used in the management of neuropathic pain and fibromyalgia. These three treatments are utilised for treatment of the same condition without any current evidence to compare efficacy or to guide clinicians in the most appropriate therapy for a given patient.

The current paradigm in the management of pain utilises multimodal analgesia, in which analgesics with different mechanisms of action are used in combination to harness presumed additive (and hopefully synergistic) effects and limit dose related adverse effects. However studies of analgesics are only infrequently examined in combination, which leads to a lack of information regarding the additive nature of any effects (positive or negative).

Within the Sir Charles Gairdner Hospital (SCGH) Pain Management Department, patients are admitted as day stay patients for brief (1-2 hour) infusions of either lidocaine or ketamine, usually repeated on a weekly basis for a series of three infusions.

The aim of this pilot study is to assess the efficacy and tolerability of an infusion utilising a combination of lidocaine, magnesium sulphate and ketamine in the treatment of neuropathic pain, CRPS and fibromyalgia. Data will be used to identify appropriate doses and guide the creation of a later comparative study.

This study will be an open label pilot study. 30 patients with peripheral neuropathic pain, CRPS or fibromyalgia will be recruited from the Pain Management Department at SCGH. Patients will receive four intermittent infusions utilising a combination of lidocaine, magnesium sulphate and ketamine.

Patients will be assessed for intra-infusion adverse effects and on a fortnightly basis for 6 weeks and then at 3 months following the final infusion. Data will be collected via phone interview as well as utilising the ePPOC questionnaire which includes multiple pain measures (BPI, DASS21, PSEQ,PCS, GRoC and medication usage) and is routinely used in the Pain Management Department at SCGH to assess efficacy of therapy.

Following completion of the study, data obtained along with data from a prior audits of lidocaine and ketamine infusions for the treatment of neuropathic pain will be used to design a double blind comparative study.

  • Australia
  • Neuropathic Pain
  • Complex Regional Pain Syndrome
  • Fibromyalgia

Total execution time in seconds: 0.31234002113342